1
|
Fuentes D, Cabezas-Cruz A, Mesa C, Carmenate T, Martínez D, Valdés-Zayas A, Montero E, Pérez R. Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice. J Breast Cancer 2022; 25:218-232. [PMID: 35657001 PMCID: PMC9250876 DOI: 10.4048/jbc.2022.25.e18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 11/24/2021] [Accepted: 04/03/2022] [Indexed: 11/30/2022] Open
Abstract
Purpose Methods Results Conclusion
Collapse
Affiliation(s)
- Dasha Fuentes
- National Center for Laboratory Animal Breeding (CENPALAB), Havana, Cuba
| | - Alejandro Cabezas-Cruz
- Anses, INRAE, Ecole Nationale Vétérinaire D'Alfort, UMR BIPAR, Laboratoire de Santé Animale, Maisons-Alfort, France
| | - Circe Mesa
- Center of Molecular Immunology (CIM), Havana, Cuba
| | | | | | | | | | | |
Collapse
|
2
|
Bremnes RM, Busund LT, Kilvær TL, Andersen S, Richardsen E, Paulsen EE, Hald S, Khanehkenari MR, Cooper WA, Kao SC, Dønnem T. The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol 2016; 11:789-800. [PMID: 26845192 DOI: 10.1016/j.jtho.2016.01.015] [Citation(s) in RCA: 331] [Impact Index Per Article: 41.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Revised: 01/24/2016] [Accepted: 01/26/2016] [Indexed: 12/25/2022]
Abstract
A malignant tumor is not merely an accumulation of neoplastic cells, but constitutes a microenvironment containing endothelial cells, fibroblasts, structural components, and infiltrating immune cells that impact tumor development, invasion, metastasis, and outcome. Hence, the evolution of cancers reflects intricate cellular and molecular interactions between tumor cells and constituents of the tumor microenvironment. Recent studies have shed new light on this complex interaction between tumor and host immune cells and the resulting immune response. The composition of the immune microenvironment differs across patients as well as in cancers of the same type, including various populations of T cells, B cells, dendritic cells, natural killer cells, myeloid-derived suppressor cells, neutrophils, and macrophages. The type, density, location, and organization of immune cells within solid tumors define the immune contexture, which has proved to be a major determinant of tumor characteristics and patient outcome. Lung cancer consists mostly of non-small cell lung cancer (85%); it is our most deadly malignant disease, with the 5-year survival rate being merely 15%. This review focuses on the immune contexture; the tumor-suppressing roles of tumor-infiltrating lymphocytes; and the relevance of this immune contexture for cancer diagnostics, prognostication, and treatment allocation, with an emphasis on non-small cell lung cancer.
Collapse
Affiliation(s)
- Roy M Bremnes
- Institute of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway; Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway.
| | - Lill-Tove Busund
- Institute of Medical Biology, The Arctic University of Norway, Tromsø, Norway; Department of Pathology, University Hospital of Northern Norway, Tromsø, Norway
| | - Thomas L Kilvær
- Institute of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway; Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway
| | - Sigve Andersen
- Institute of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway; Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway
| | - Elin Richardsen
- Institute of Medical Biology, The Arctic University of Norway, Tromsø, Norway; Department of Pathology, University Hospital of Northern Norway, Tromsø, Norway
| | - Erna Elise Paulsen
- Institute of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway; Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway
| | - Sigurd Hald
- Institute of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway; Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway
| | | | - Wendy A Cooper
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; School of Medicine, University of Western Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, New South Wales, Australia
| | - Steven C Kao
- Chris O'Brien Lifehouse, Sydney, New South Wales, Australia; Asbestos Diseases Research Institute, Sydney, New South Wales, Australia; University of Sydney, Sydney, New South Wales, Australia
| | - Tom Dønnem
- Institute of Clinical Medicine, The Arctic University of Norway, Tromsø, Norway; Department of Oncology, University Hospital of Northern Norway, Tromsø, Norway
| |
Collapse
|